Dawn S Chandler, PhD

College

College of Medicine

Department/Division

Pediatrics

Academic Title

Assoc Professor

Research Program

Molecular Biology and Cancer Genetics

Research Interest

>Cancer ● Muscular Atrophy, Spinal ● Rhabdomyosarcoma ● DNA Damage ● Breast Cancer ● Loss of Heterozygosity ● Anoxia ● Carcinoma, Renal Cell ● von Hippel-Lindau Disease ● Myopathies, Structural, Congenital

Dawn Chandler, PhD, is a member of the Molecular Biology and Cancer Genetics Program at the OSUCCC – James, where her work focuses on the regulation of pre-mRNA splicing and how its disruption can lead to pediatric diseases such as cancer.

In one recent study, her team’s research identified for the first time a clear mechanism for regulating damage-induced oncogene MDM2 splicing. The work offers potential strategies for manipulating MDM2 expression via splicing modulation.

Dr. Chandler has co-authored numerous articles in well-respected publications, including Human Molecular Genetics, Nucleic Acids Research and the Journal of Biological Chemistry.

Office Location

WA5023 Columbus Children's Research Institute

700 Children's Drive, Columbus, OH 43205

614-722-5302

614-722-5895

Dawn.Chandler@nationwidechildrens.org;chandler.135@osu.edu

Publications

RNA Splicing and Disease: Animal Models to Therapies.

Montes M, Sanford BL, Comiskey DF, Chandler DS

Trends Genet 35 68-87 01/01/2019
A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo.

Comiskey DF Jr, Jacob AG, Sanford BL, Montes M, Goodwin AK, Steiner H, Matsa E, Tapia-Santos AS, Bebee TW, Grieves J, La Perle K, Boyaka P, Chandler DS

Oncogene 37 95-106 01/04/2018
SMN regulation in SMA and in response to stress: new paradigms and therapeutic possibilities.

Dominguez CE, Cunningham D, Chandler DS

Hum Genet 136 1173-1191 01/01/2017
Splicing factor SRSF1 negatively regulates alternative splicing of MDM2 under damage.

Comiskey DF Jr, Jacob AG, Singh RK, Tapia-Santos AS, Chandler DS

Nucleic Acids Res 43 4202-18 04/30/2015
The splicing factor FUBP1 is required for the efficient splicing of oncogene MDM2 pre-mRNA.

Jacob AG, Singh RK, Mohammad F, Bebee TW, Chandler DS

J Biol Chem 289 17350-64 06/20/2014

See Full List

Back to Researcher Search

Find a Researcher
Find a Clinical Trial

Please enter a keyword (i.e. Name, Research Interest) or choose a Research Program

By Name or Keyword

OR

By Research Program

Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator

Dawn S Chandler, PhD

College

Department/Division

Academic Title

Research Program

Research Interest

Office Location

Publications

RNA Splicing and Disease: Animal Models to Therapies.

A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo.

SMN regulation in SMA and in response to stress: new paradigms and therapeutic possibilities.

Splicing factor SRSF1 negatively regulates alternative splicing of MDM2 under damage.

The splicing factor FUBP1 is required for the efficient splicing of oncogene MDM2 pre-mRNA.

OR

OR

Search for Clinical Trials

Find a Scientific Publication

Dawn S Chandler, PhD

College

Department/Division

Academic Title

Research Program

Research Interest

Office Location

Publications

RNA Splicing and Disease: Animal Models to Therapies.

A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo.

SMN regulation in SMA and in response to stress: new paradigms and therapeutic possibilities.

Splicing factor SRSF1 negatively regulates alternative splicing of MDM2 under damage.

The splicing factor FUBP1 is required for the efficient splicing of oncogene MDM2 pre-mRNA.

Related Links

OR

OR

Search for Clinical Trials

Find a Scientific Publication